SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that based on a review of data from its Contrave® Phase IIb trial, patients assigned to Contrave dosage groups demonstrated a 50% reduction in the prevalence of metabolic syndrome. Metabolic syndrome is a group of risk factors associated with obesity that may increase the risk of developing diabetes or cardiovascular disease. According to the American Heart Association, metabolic syndrome affects an estimated 47 million Americans.
